6547
高端疫苗
+0.80 (+1.34%)60.502,486成交張數–本益比5.52股價淨值比0.00%殖利率2026-09-16資料日期
綜合損益表公開資訊觀測站申報原值 · 年度(第 4 季累計) · 每一格 = 該期對去年同期的成長率 · 未來期間為分析師共識預估(2026-09-09)
營業收入2025613年增 +1.2%
毛利率202559.5%最新一期
營業利益率2025-43.3%最新一期
每股盈餘2025-0.86
| 會計項目 | 走勢 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 預估 1 家 | 2027 預估 1 家 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業收入合計 | – | – | +927.4% | – | -88.9% | +6.7% | +55.4% | +1.2% | +41.1% | +83.7% | |
| 營業成本合計 | – | – | – | – | -40.8% | -72.4% | +31.2% | +18.8% | – | – | |
| 營業毛利（毛損） | – | – | +581.8% | – | -109.2% | – | +72.2% | -8.0% | +42.3% | +83.7% | |
| 營業毛利（毛損）淨額 | – | – | +581.8% | – | -109.2% | – | +72.2% | -8.0% | – | – | |
| 推銷費用 | – | – | – | -2.0% | +871.4% | +115.5% | +42.9% | -11.2% | – | – | |
| 管理費用 | – | -4.4% | +27.2% | +66.9% | -21.2% | -22.0% | +11.3% | -3.8% | – | – | |
| 研究發展費用 | – | +35.7% | +26.1% | +75.6% | -4.5% | +5.3% | -81.6% | +52.8% | – | – | |
| 營業費用合計 | – | +29.7% | +27.5% | +73.9% | -1.3% | +9.1% | -62.5% | +16.3% | – | – | |
| 營業利益（損失） | – | – | – | – | -259.4% | – | – | – | – | +504.2% | |
| 利息收入 | – | – | – | +85.5% | +177.6% | +995.1% | -44.5% | -36.7% | – | – | |
| 其他收入 | – | +516.0% | – | +468.9% | -84.5% | -73.4% | -100.0% | – | – | – | |
| 其他利益及損失淨額 | – | – | – | -72.2% | +65.2% | -180.9% | – | -200.5% | – | – | |
| 財務成本淨額 | – | +85.4% | -14.2% | -63.3% | +346.7% | +39.7% | -49.7% | -53.4% | – | – | |
| 營業外收入及支出合計 | – | – | – | +398.3% | -86.2% | -12.5% | +20.8% | -124.6% | – | – | |
| 稅前淨利（淨損） | – | – | – | – | -204.6% | – | – | – | – | – | |
| 繼續營業單位本期淨利（淨損） | – | – | – | – | -204.6% | – | – | – | – | – | |
| 本期淨利（淨損） | – | – | – | – | -204.6% | – | – | – | – | – | |
| 透過其他綜合損益按公允價值衡量之權益工具投資未實現評價損益 | – | – | – | – | – | -166.0% | – | -281.5% | – | – | |
| 不重分類至損益之項目： | – | – | – | – | – | -166.0% | – | -281.5% | – | – | |
| 國外營運機構財務報表換算之兌換差額 | – | – | – | – | – | -99.4% | – | -100.0% | – | – | |
| 後續可能重分類至損益之項目： | – | – | – | – | – | -99.4% | – | -100.0% | – | – | |
| 其他綜合損益（淨額） | – | – | – | – | – | -165.7% | – | -281.2% | – | – | |
| 本期綜合損益總額 | – | – | – | – | -198.7% | – | – | – | – | – | |
| 母公司業主（淨利∕損） | – | – | – | – | -204.6% | – | – | – | – | +290.2% | |
| 母公司業主（綜合損益） | – | – | – | – | -198.7% | – | – | – | – | – | |
| 基本每股盈餘 | – | – | – | – | -168.6% | – | – | – | – | +284.2% | |
| 稀釋每股盈餘 | – | – | – | – | -169.3% | – | – | – | – | – | |
| 繼續營業單位淨利（淨損） | – | – | – | – | -169.3% | – | – | – | – | – |
金額為公司申報原值除以一千(百萬元,四捨五入),每股金額為元。年度為第 4 季的年初至今累計數。最右邊的預估欄是分析師共識預估(2026-09-09),營收、營業利益、母公司淨利、每股盈餘直接取共識平均,毛利由共識營收乘上共識毛利率推算,不是公司財測。走勢條是歷史各期的相對大小,藍為正、綠為負。年增以去年同期為基期,基期非正數或變動超過十倍時不列。 權益變動表在申報資料分頁。